Schonfeld Strategic Advisors LLC Reduces Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Schonfeld Strategic Advisors LLC lowered its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,410 shares of the biotechnology company’s stock after selling 11,952 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in Sarepta Therapeutics were worth $6,008,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in SRPT. Charles Schwab Investment Management Inc. increased its stake in Sarepta Therapeutics by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after acquiring an additional 12,000 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth $3,829,000. Nordea Investment Management AB grew its holdings in shares of Sarepta Therapeutics by 19.1% during the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after purchasing an additional 10,815 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after purchasing an additional 84,926 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in Sarepta Therapeutics by 24.4% in the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock valued at $10,315,000 after buying an additional 16,658 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Trading Up 0.6 %

SRPT opened at $62.78 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25. The company has a market cap of $6.17 billion, a P/E ratio of 50.22 and a beta of 0.93. The business’s 50-day simple moving average is $73.73 and its 200-day simple moving average is $104.12.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several research analyst reports. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $161.00 to $87.00 in a research note on Monday, March 31st. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Cantor Fitzgerald restated an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. HC Wainwright restated a “neutral” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Finally, Morgan Stanley cut their price objective on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating on the stock in a report on Friday, April 11th. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $158.70.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.